Agamree is an innovative glucocorticoid drug with Vamorolone as its main active ingredient. It is the first treatment for Duchenne Muscular Dystrophy (DMD) to receive full approval in the European Union, providing a breakthrough therapeutic option for DMD patients aged 2 years and above. Its unique mechanism enables it to effectively control muscle inflammation and slow down disease progression.

How Effective is Agamree in Treatment?

Agamree has demonstrated significant clinical efficacy and safety advantages in the treatment of Duchenne Muscular Dystrophy.

Clinical Efficacy Data

Key clinical trials showed that after 24 weeks of treatment with a daily dose of 6mg/kg, DMD patients achieved an average improvement of 25 meters in the 6-Minute Walk Distance (6MWD) and a 2.5-point increase in the North Star Ambulatory Assessment (NSAA) score. Compared with traditional glucocorticoids, Agamree maintains similar efficacy while reducing the incidence of growth inhibition and abnormal bone metabolism.

Characteristics of Mechanism of Action

Vamorolone is a selective glucocorticoid receptor modulator. It retains anti-inflammatory effects while reducing some genomic effects. This unique mechanism allows it to effectively control muscle inflammation, slow disease progression, and reduce the typical side effects of traditional glucocorticoids.

Benefits of Long-Term Treatment

Long-term follow-up data indicate that continuous use of Agamree can stably maintain patients' motor function and reduce the annual rate of functional decline. The drug is effective for DMD patients with all genotypes, without being restricted by mutation types, providing treatment hope for a wide range of patient groups.

Precautions for Agamree Administration

Standardized use of Agamree is crucial for its therapeutic effect.

Principles of Dosage Adjustment

The standard dose is 6mg/kg per day, with a maximum daily dose of 300mg. Patients with impaired liver function should start with a dose of 2mg/kg. When used in combination with strong CYP3A4 inhibitors, the dose needs to be reduced to 4mg/kg. After more than 1 week of treatment, the drug should be gradually tapered off to avoid adrenal insufficiency.

Management of Adverse Reactions

Common adverse reactions include mood changes and increased appetite. Regular monitoring of growth and development, bone mineral density, and intraocular pressure is necessary. If signs of infection appear, patients should seek medical attention promptly, and dose adjustment may be considered. For patients using the drug long-term, supplementary vitamin D and calcium are recommended.

Dietary Precautions for Agamree Use

Reasonable dietary coordination helps optimize therapeutic effects and reduce adverse reactions.

Nutritional Support Recommendations

Increase intake of foods rich in calcium and vitamin D, such as dairy products and deep-sea fish, to help maintain bone health. Appropriately supplement high-quality protein to support muscle maintenance. Maintain a balanced diet and control calorie intake to prevent excessive weight gain.

Recommendations on Medication Timing

It is recommended to take the drug with meals, especially meals containing an appropriate amount of fat, which can increase the drug absorption rate by approximately 20%. Avoid taking the drug with grapefruit or star fruit, as they may affect drug metabolism. Separate the timing of medication and calcium supplementation by at least 2 hours.

Scientific diet combined with standardized medication can more effectively exert the therapeutic effect of Agamree and improve patients' quality of life.